Navigation Links
CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
Date:10/27/2008

find treatments that lead to a better overall quality of life."

In RAPID 1, patients treated with CIMZIA together with MTX reported gains in additional work and household work days per month and productive work and household work days per month as early as week 4. Over 6 months, improvements continued compared to the control group. These improvements were maintained for up to one year.

Additionally, data presented shows Health Reported Quality of Life Measurements (HRQoL) approached population norms in the "vitality" and "mental health" domains. As assessed by the Fatigue Assessment Scale of 1 to 10, patients in the trial also reported a mean reduction in fatigue to 3.1 points at week 100 with CIMZIA together with MTX treatment.

Notes to Editors:

RAPID Clinical Trials Program

The international, multi-center, double-blind placebo-controlled RAPID (RA PreventIon of structural Damage) clinical trials were designed to establish the efficacy and tolerability of CIMZIA(R) (certolizumab pegol) together with methotrexate (MTX) in the treatment of active rheumatoid arthritis who did not adequately respond to conventional treatment. The program is comprised of two large, international, multi-center placebo-controlled studies - RAPID 1 (027) and RAPID 2 (050).

In the year-long RAPID 1 trial, patients randomly received one of three treatment regimens: 393 patients received CIMZIA 400 mg at weeks 0, 2 and 4, then CIMZIA 200 mg together with MTX every two weeks; 390 patients received CIMZIA 400 mg together with MTX every 2 weeks; 199 patients received placebo together with MTX every 2 weeks. RAPID 1 met co-primary endpoints: ACR20 response rate(a) at week 24 and the change from baseline in mTSS(b) at week 52. An open-label extension study continued to evaluate the effects of CIMZIA over two years.

In the six-month RAPID 2 trial, 619 patients randomly received one of three treatment regimens: 246 patients received CIMZIA 400 mg at w
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
2. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
3. Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohns Disease
4. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
5. Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients
6. Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project
7. IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP)
8. Fralex provides update on timing of interim analysis results
9. Vanda Pharmaceuticals Provides Update on Iloperidone
10. Study Demonstrates That AHCC(R) Provides Immune Enhancement Against the West Nile Virus
11. Study Reveals Novel LCD Solution Provides Significant Benefits Versus Calcipotriol In Treatment Of Moderate Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or the "Company"), a ... products and a licensed producer ("LP") to cultivate marijuana ... Canada ) ("MMPR"), is pleased to announce that ... the transaction announced on March 11, 2015 with Medna ... a total of 20,156,790 common shares of T-Bird (45% ...
(Date:4/23/2015)...  Edwards Lifesciences Corporation (NYSE: EW ), the ... hemodynamic monitoring, today reported net income for the quarter ... diluted share.  Net income for the same period a ... share, and non-GAAP net income was $82.1 million, or ... the quarter ended March 31, 2015 increased 13.0 percent to ...
(Date:4/23/2015)... 2015 Nektar Therapeutics (Nasdaq: NKTR ) will ... 31, 2015 on Thursday, April 30, 2015, after the close ... chief executive officer, will host a conference call to review ... Pacific Time (PT). The press release and ... accessed through a link that is posted on the home ...
Breaking Medicine Technology:T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 2T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 3Edwards Lifesciences Reports First Quarter Results 2Edwards Lifesciences Reports First Quarter Results 3Edwards Lifesciences Reports First Quarter Results 4Edwards Lifesciences Reports First Quarter Results 5Edwards Lifesciences Reports First Quarter Results 6Edwards Lifesciences Reports First Quarter Results 7Edwards Lifesciences Reports First Quarter Results 8Edwards Lifesciences Reports First Quarter Results 9Edwards Lifesciences Reports First Quarter Results 10Edwards Lifesciences Reports First Quarter Results 11Edwards Lifesciences Reports First Quarter Results 12Edwards Lifesciences Reports First Quarter Results 13Edwards Lifesciences Reports First Quarter Results 14Edwards Lifesciences Reports First Quarter Results 15Edwards Lifesciences Reports First Quarter Results 16Nektar to Announce Financial Results for the First Quarter 2015 on Thursday, April 30, 2015, After Close of U.S.-Based Financial Markets 2
... , , , , , , WOONSOCKET, R.I., Dec. ... select CVS/pharmacy stores are now offering H1N1 vaccine in 20 ... restrictions for receiving H1N1 vaccines continue, many states have lifted ... shot while supplies last. In addition, seasonal influenza vaccine ...
... SALT LAKE CITY, Dec. 16 TechniScan, Inc. ... device company engaged in the development and commercialization of an ... PhD, has been appointed to the TechniScan Board of Directors. ... experience running small to large medical devices companies, including GE ...
Cached Medicine Technology:CVS/pharmacy and MinuteClinic Providing H1N1 Vaccines in 20 States and Washington, D.C. 2CVS/pharmacy and MinuteClinic Providing H1N1 Vaccines in 20 States and Washington, D.C. 3CVS/pharmacy and MinuteClinic Providing H1N1 Vaccines in 20 States and Washington, D.C. 4In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 2In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 3
(Date:4/25/2015)... Parker and Sons projects growth in 2015. The ... Arizona alongside the growing economy. As a result, Parker and ... to help account for the rising need for heating, cooling, ... something we are enthusiastic about. It means growth for us, ... Parker and Sons. , Indeed, Parker and Sons has been ...
(Date:4/25/2015)... (PRWEB) April 25, 2015 On Friday, ... of RFID Journal’s annual Best Implementation Award. This ... demonstrated the best use of RFID technology to improve ... is the company that best demonstrates how RFID is ... presented at RFID Journal Live! 2015 in San Diego, ...
(Date:4/24/2015)... Constellations Recovery celebrates the opening of the ... 35 miles from New York City, Constellations Recovery was ... while recovering from addiction. The Open House, which is ... doctors and treatment centers to see the residence, tour ... offered by Constellations Recovery.,  , The newly opened facility ...
(Date:4/24/2015)... Foothill Ranch, California (PRWEB) April 24, 2015 ... that has a wide range of capabilities and services ... etc. , Ryadon's Quantity Discount Program will be ... ) as follows: , Order 4-19: Receive 10% discount ... Can Benefit by Using the Drawer Slides Products, ...
(Date:4/24/2015)... 24, 2015 Lipitor lawsuits ( ... the federal multidistrict litigation underway in U.S. District ... documents, the parties involved in the proceeding submitted ... among other things, preparation for the litigation’s upcoming ... both plaintiffs and defendants have conducted depositions of ...
Breaking Medicine News(10 mins):Health News:Parker and Sons Plans to Expand in 2015 2Health News:Seeonic’s Industry Leading Technology Powers Interstate Batteries to Winning Award 2Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 2Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 3Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 2Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 3Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 2Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 3
... The following is a,statement by Reverend Carlton W. Veazey, ... "On the 35th anniversary of Roe v. Wade, ... that abortion will be safe, legal, and available,if and ... v. Carhart,opinion and the ,fetal personhood, initiatives and outright ...
... Inc, (TSX:,DAX) (NASDAQ: DRAX ) has received approval ... Normal Course Issuer Bid (NCIB) to,purchase up to 4,072,054 ... shares in the public float as at January 14, ... DRAXIS were issued and,outstanding., Purchases may begin on ...
... of Pharmaceutical and CRO Experience ... to Key Leadership Role, CINCINNATI, Jan. 16 Kendle ... (CRO), today,announced Dr. Ross J. Horsburgh has joined the company ... he will lead the,company,s overall expansion in Asia/Pacific and will ...
... (HCC) patients in China may be treated with Traditional ... its effectiveness. These stated that a research group in ... PTEN in HCC, which may suppress tumor cell growth ... research article published on January 7, 2008 in ...
... Universit Lavals Faculty of Medicine and Robert-Giffard Hospital has ... antipsychotic drugswhich in extreme cases can be as high ... through a specially designed weight control program. The researchers ... report the details of their findings in a recent ...
... for pepsin, a digestive enzyme specifically produced in the ... different biochemical and immunological properties, PGI and PGII. Serum ... and functional changes in the stomach, and used as ... has been focused on the identification of individuals for ...
Cached Medicine News:Health News:Statement of the Reverend Carlton W. Veazey, President and CEO of the Religious Coalition for Reproductive Choice, on the 35th Anniversary of Roe v. Wade 2Health News:DRAXIS Share Buyback Approved by TSX 2Health News:DRAXIS Share Buyback Approved by TSX 3Health News:DRAXIS Share Buyback Approved by TSX 4Health News:Kendle Appoints Industry Veteran to Lead Asia/Pacific Expansion 2Health News:Kendle Appoints Industry Veteran to Lead Asia/Pacific Expansion 3Health News:How does Fu-Zheng-Jie-Du-Decoction act on PTEN expression in hepatocellular carcinoma? 2Health News:Weight gain induced by antipsychotic drugs can be avoided 2Health News:What are the essential characteristics of serum PG in Chinese? 2
Angled 45 degree shafts with 10.5 mm tying platform. 1 mm of tip is crisscross serrated. Serrated handle with dull finish. Most popular size or model. Overall length 3.2 inches....
Angled shafts with 10 mm tying platform. True round knurled handle in the closed position with polished finish. Overall length 4.2 inches....
Angled 45 degree shafts 8 mm from tip to bend with 5 mm tying platform. Serrated handle with dull finish. Overall length 3.3 inches....
Ultra-fine 5 mm tying platform is valuable when manipulating delicate 10-0 and 11-0 sutures. Pin in handle keeps tips in alignment. Shafts available straight or angled 45 degrees, 8 mm from tip. Angl...
Medicine Products: